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Background: Stroke is the second most common cause of mortality and the leading cause of neurological
disability, cognitive impairment and dementia worldwide. Nimodipine is a dihydropyridinic calcium antagonist with
a role in neuroprotection, making it a promising therapy for vascular cognitive impairment and dementia.
Methods/design: The NICE study is a multicenter, randomized, double-blind, placebo-controlled study being
carried out in 23 centers in China. The study population includes patients aged 30–80 who have suffered an
ischemic stroke (≤7 days). Participants are randomly allocated to nimodipine (90 mg/d) or placebo (90 mg/d). The
primary efficacy is to evaluate the level of mild cognitive impairment following treatment of an ischemic stroke
with nimodipine or placebo for 6 months. Safety is being assessed by observing side effects of nimodipine.
Assuming a relative risk reduction of 22%, at least 656 patients are required in this study to obtain statistical power
of 90%. The first patient was recruited in November 2010.
Discussion: Previous studies suggested that nimodipine could improve cognitive function in vascular dementia
and Alzheimer’s disease dementia. It is unclear that at which time-point intervention with nimodipine should occur.
Therefore, the NICE study is designed to evaluate the benefits and safety of nimodipine, which was adminstered
within seven days, in preventing/treating mild cognitive impairment following ischemic stroke.Background
It is well established that stroke contributes to about 5.4
million deaths per year and is the leading cause of
neurological disability worldwide [1,2]. Cerebrovascular
disease is now one of the main diseases affecting the
health of Chinese people [3,4]. Motor and sensory im-
pairment, cognitive impairment and even post-stroke de-
mentia can be induced by stroke. Cognitive impairment
and dementia following stroke can severely lower the
ability of perform daily activities and decrease quality of
life (QOL) in patients with stroke, and increase the rate
of disability and death.* Correspondence: yongjunwang111@yahoo.com.cn; happyft@sina.com
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reproduction in any medium, provided the orCognitive impairment was proposed as a prognostic
index of stroke by the Hachinski group in 2007 [5]. Sub-
clinical stroke and leukodystrophy may cause some cogni-
tive changes in older patients, such as disturbances of
thinking and reasoning, disturbances of memory and recall
of recent events, and disorders of social behavior and de-
pression [6,7]. A population-based study in Japan observed
that 42.5% of early-onset dementia cases were related to
vascular diseases [8]. Previous studies comparing patients
with and without a stroke found that stroke was strongly
associated with incident dementia [9-13]. Thus, prevention
is crucial for both reduction of frequency of post-stroke
cognitive decline and dementia and decreasing economic
burden following stroke.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wang et al. BMC Neurology 2012, 12:88 Page 2 of 7
http://www.biomedcentral.com/1471-2377/12/88The worldwide therapeutic model for stroke treatment is
transforming from a focus on improvement of somatic
function to improving the whole QOL, including prevent-
ing and treating post-stroke dementia or vascular cognitive
impairment (VCI) [14]. Post-stroke cognitive impairment
consists of vascular dementia, mixed dementia and non-
dementia cognitive impairment [15,16]. Vascular dementia
can be been treated with cholinesterase inhibitors
(Donepezil and Rivastigmine), N-methyl d-aspartate
(NMDA) receptor antagonists (Memantine) and some
nootropic drugs. However, previous studies showed that
cholinesterase inhibitors had controversial roles in treating
vascular diseases [17-19]. Memantine had only a small ef-
fect on improving cognitive impairment [20]. In addition,
previous studies did not supply any supportive evidence
for the effect of Piracetam on vascular cognitive impair-
ment [21]. So far, clinical trials on the pharmacotherapy of
vascular dementia for the above-mentioned drugs have
yielded unsatisfactory results. In contrast, an evidence-
based meta-analysis demonstrated that nimodipine could
improve cognitive function in vascular dementia, Alzhei-
mer's disease (AD) dementia and mixed dementia with
good tolerance [22]. Also, vascular dementia can be partly
induced by altering intracellular calcium metabolism, al-
though the mechanisms underlying the impact of cerebro-
vascular diseases on vascular dementia are not fully
understood [23-25]. Therefore, the evidence is needed to
choose a valid option for preventing and treating cognitive
impairment after a stroke.
Rational and discussion
Nimodipine is a dihydropyridinic calcium antagonist that
quickly and easily crosses the BBB and reaches a high con-
centration in cerebrospinal fluid (CSF). It improves cere-
bral perfusion after acute ischemia [26] and reduces
neurological deficits [27-29]. It has specific affinity for re-
ceptor operated calcium channels in cerebral vessels and
for specific membrane-located receptor sites that may be
associated with the pharmacological action of nimodipine
in the brain [30,31]. Results from in vivo research showed
that nimodipine also has a high affinity for specific binding
sites in the cortex, the dentate gyrus and the hippocampus,
which are known to be the core regions involved in cogni-
tive function [32]. Based on this evidence, many studies
have tried to elucidate the role of nimodipine in treating
cognitive impairment. A published Meta-analysis from 14
randomized, double-blind and control clinical trials (3166
cases) suggested that nimodipine (90 mg/d, 12–26 weeks)
could improve the cognitive deficits caused by unclassified
disease, Alzheimer’s disease, cerebrovascular disease, or
mixed Alzheimer’s and cerebrovascular disease [22]. A wide
variety of scales, such as the mini-mental state examination
(MMSE), short cognitive performance test (SKT), clinical
global impression (CGI), Sandoz clinical assessment geriatricscale (SCAG) and Alzheimer’s disease assessment score-
cognitive component (ADAS-cog), were adopted to evaluate
cognitive impairment in this Meta-analysis. The results sug-
gested that nimodipine could significantly delay the decrease
in SCAG score [WMD (weighted mean difference) -11.75,
95% CI −15.64–-7.85, P<0.00001] and CGI (WMD −1.31,
95% CI −1.73–-0.89, P <0.00001) at 12 weeks following
stroke [22].
The first randomized, double-blind, controlled trial fo-
cusing on subcortical vascular dementia and multiple in-
farction dementia presented the results in 2005 [33].
This study noted a 22.4% reduction in deterioration (3 or
more point-drop versus baseline) on the MMSE within a
52-week period in nimodipine-treated patients when com-
pared with the placebo group, who had similar demo-
graphic characteristics. There was also a significant delay
in the deterioration of SCAG scores and significant im-
provement in SCAG scores.
The pivotal principal of cognitive impairment prevention
following stroke is to intervene early rather than cure late.
An important study in Hong Kong (China) was carried out
to examine the effectiveness of nimodipine prevention/
therapy on cognitive impairment in acute cerebral infarc-
tion patients, with the aim of demonstrating the effective-
ness of early intervention after stroke [34]. Although this
study was a single-blind randomized controlled trial and
enrolled 100 patients, promising results were found in
acute cerebral infarction patients. In the intervention
patients, Fuld object-memory evaluation (FOME) mean
scores were significantly improved and the death rate did
not increase within a 12-week period.
An important consideration is at which time-point inter-
vention with nimodipine should occur. This varies be-
tween studies, as most are administered at a chronic stage
(i.e. >6 months after the stroke) and 2 weeks after the
stroke [22,35]. However, a series of chain reactions induce
a large amount of neuronal damage at acute and subacute
stages of stroke [36]. Theoretically, nimodipine could have
clinical benefits due to its ability to modulate blood vessels
and protect neurons, especially its probable ability to regu-
late the capillary with relatively intact structure and func-
tions in the severely injured brain [27,30,37,38]. It is thus
conceivable that it is clinically beneficial to begin nimodi-
pine therapy at early stage after the stroke.
The aim of this study is therefore to evaluate the clin-
ical efficacy and safety of nimodipine, administered
within seven days after an acute ischemic stroke, in the
prevention of mild cognitive impairment.
Methods/design
Study design
The NICE study is a phase IV clinical designed as a mul-
ticenter, randomized, double-blind, placebo-controlled,
parallel-group study, which is being carried out in 23
Wang et al. BMC Neurology 2012, 12:88 Page 3 of 7
http://www.biomedcentral.com/1471-2377/12/88centers in China (Additional file 1: Appendix). The study
design is presented in Figure 1. The inclusion criteria
and major exclusion criteria are shown as the following.
The inclusion criteria are:
 Male or female, aged 30-80;
 Acute ischemic stroke diagnosed according to ICD-
10 and CT/MRI criteria;
 ≤7d after the stroke;
 MMSE score >Dementia threshold corrected based
on educational year (>17 scores, >20 scores and >24
scores for illiterate, primary school, and above
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Figure 1 The NICE study flowchart. The intention-to-treat (ITT). MoCA <26 scores for >12 educational years (or <25
scores for ≤12 educational years);
 Hachinski ≥7 scores;
 Expected good compliance with the therapy and follow-
up. Already obtained written informed consent form.
Major exclusion criteria are:
 Pregnant or lactating women;
 History of mental diseases (eg. Schizophrenia and
serious anxiety depression);
 Patients with AD, Parkinson's disease, frontotemporal






1 month follow-up: physical 
examination, commitment 
treatment record, safety 
evaluation, vascular
dementia assessment
3 month follow-up: physical 
examination, laboratory 
examination, commitment 
treatment record, safety 
evaluation, vascular dementia 
assessment, MMSE, MoCA, 
ADAS-cog, FAB evaluation 
6 month follow-up: physical 
examination, laboratory examination, 
commitment treatment record, safety 
evaluation, vascular dementia 
assessment, MMSE, MoCA, ADAS-cog, 
FAB evaluation, MRI (optional), 










within 7d after attack
trument (CASI) 
ts experienced  
ays to select  
 criteria. Each 
consent form. 
Wang et al. BMC Neurology 2012, 12:88 Page 4 of 7
http://www.biomedcentral.com/1471-2377/12/88existing dementia diagnosed before the stroke or the
past definite cognitive impairment);
 Dementia of other causes (eg. injury of central
nervous system, tumor, infection, metabolic disease,
hydrocephalus at normal pressure, deficiency of folic
acid/vitamin B12 and hypothyroidism);
 Patients with other influencing factors for cognition
evaluation (eg. aphasia, serious auditory/visual
impairment and hemiplegia at dominant side);
 Patients with contraindications for dihydropyridines;
 Patients with serious arrhythmia, heart rate > 120 bpm
(or < 50 bpm); ever myocardial infarction within 6
months; BP < 90/60 mmHg; serious heart failure
(unable to engage in any physical activity, and
dyspnea and cardiac edema or angina pectoris at rest);
 Patients having serious kidney incompetence: Creatinine
>1.5 times of upper limit of normal value (ULN);
 Patients with serious liver incompetence: AST/ALT
level >3 times of ULN;
 History of known allergy;
 History of blood coagulation dysfunction,
hemorrhagic disease, thrombocytopenia,
leukocytopenia or neutropenia, serious anemia,
Hb < 100 g/L;
 History of serious gastrointestinal disease;
 Patients with any known malignant tumor;
 Patients with epilepsy and/or ever having
antiepileptic drugs.
The diagnosis of acute ischemic stroke is determined by
clinical examination and magnetic resonance imaging
(MRI). The threshold of MMSE scores is corrected based
on years of education (>17 scores, >20 scores and >24 scores
for illiterate, primary school, and above middle school re-
spectively) [39]. Montreal cognitive assessment (MoCA)
scores are <26 for >12 educational years, and <25 for ≤12
educational years [40]. Hachinski scores are≥7 [41].
Ethics and informed consent
The study is being performed in accordance with the eth-
ical principles proclaimed in the Declaration of Helsinki
in 1964, and revised in Tokyo in 2004. The study protocol
has been reviewed by independent ethics committees in
China, and by coordinators, investigators, and sponsors in
accordance with local regulations. According to local
requirements, thorough study information is provided to
patients and written informed consent is obtained from
each patient or surrogate family member before inclusion
in the study. The NICE study is registered with clinical-
trials.gov (registration number: NCT01220622).
Treatment and follow-up
Inclusion and exclusion criteria are verified and it is
decided for each patient whether the study drug can beadministered within 7 days after the onset of ischemic
stroke. Patients are given nimodipine, 30 mg, tid, three
tablets daily, or placebo, 30 mg, tid, three tablets daily.
Intervention allocation is based on balanced, randomized,
permuted blocks which were produced by a third party sta-
tistician who was blinded to the whole protocol. The study
interventions are identical in appearance, and investigators
and patients are blinded to intervention allocation. Aside
from basic treatment for acute ischemic stroke, cholinester-
ase inhibitors, NMDA receptor antagonists, or drugs from
the racetam family cannot be used in this study. The fol-
lowing information is collected at the baseline assessment:
(1) Demographic data;
(2) Blood pressure, temperature, and pulse rate;
(3) Time from stroke onset;
(4) Medical history;
(5) Previous and ongoing medications;
(6) Assessing vascular dementia according to National
Institute of Neurological Disorders and Stroke, -and
the Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (NINDS-AIREN)
criteria;
(7) NIH stroke scale (NIHSS), ADAS-cog, Frontal
assessment battery (FAB), Alberta stroke program
early CT score (ASPECTS), Fazekas, The cholinergic
pathways hyperintensities scale (CHIPS).
Follow-up visits are carried out at 1, 3, and 6 months
(Figure 1). A physical examination is performed, and con-
comitant treatments are recorded at every visit. Compli-
ance is determined by counting tablets at every visit.
Cognitive function is assessed using MMSE, MoCA,
ADAS-cog, and FAB, at 3 and 6 months.
Safety is evaluated at every visit, including adverse
events (AE) and serious adverse events (SAE), regardless
of whether they are related to the administration of the
study drug or course of therapy. All AE or SAE are
reported and followed up completely. Laboratory tests
are collected at 3 and 6 months. Patients who break off
study intervention and informally withdraw consent will
be followed up for the duration of the study.
Primary outcome
The primary efficacy is defined as the combined results
of the following efficacy criteria:
(1) MMSE (0–30)
(2) ADAS-cog (0–70)
MMSE is widely used for assessing cognitive function
[39,42], and ADAS-cog also includes items used in
evaluating cognitive function [43,44]. These two criteria
have high reliability, and have been used in other stroke
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results is possible.
The primary end-point for evaluating the efficacy of
nimodipine for prevention/treatment of cognitive im-
pairment is 6 months after acute ischemic stroke events.
Secondary outcome
The secondary study end-points include the following
analysis:
(1) the efficacy criteria of MoCA (0–30) and FAB (0–18)
at 3 and 6 months;
(2) the efficacy criteria of MMSE and ADAS-cog at
3 months;
(3) the individual items of ADAS-cog, MoCA and FAB
at 3 months;
(4) the individual items of ADAS-cog, MoCA and FAB
at 6 months;




In this multicenter trial, we plan to enroll approximately
656 patients, with approximately 328 patients per study
group. Approximately 23 centers in China are participat-
ing, with each center enrolling about 30 patients. We
assumed that there was no significant difference between
nimodipine (90 mg/d) and placebo (90 mg/d) in the pre-
vention/treatment of aggravated cognitive impairment of
acute ischemic stroke in the 6 month follow-up. For a
statistical power of at least 90% in this trial, we esti-
mated that 656 patients are necessary to present the su-
periority of nimodipine versus placebo. This corresponds
to a relative risk (RR) reduction of 22% (RR is 0.78 for
the nimodipine group), using a two-sided test (α= 0.05,
allowing 5% dropout). The efficacy analysis is based on
an intention-to-treat method. Missing values are still
treated as missing. Patients are examined at the last
follow-up (at the occurrence of clinical event, the end of
study, or the last follow-up before drop-out). A Kaplan-
Meier curve is used to simulate the cumulative risk for
cognitive impairment in the follow-up at day 180. The
Cox proportional hazard model is used to calculate haz-
ard proportion and 95% confidence interval. Log-rank
test is used to evaluate the efficacy.
Most secondary outcome analyses will adopt the strat-
egy of the primary outcome analyses. Continuous vari-
ables (for example MoCA and FAB) will undergo multi-
variate linear regression analysis. Converted and/or
weighted least square methods are regarded as abnormal
and heterogeneous variance of remedial measures. Limit
values will undergo a validity test. The conclusion will
undergo sensitivity analysis.Study organization
The NICE trial is headed by a steering committee
(Additional file 1: Appendix), which is assisted by an inde-
pendent data safety and monitoring board (DSMB). Trial
monitoring and data management is performed by Giant
Med-Pharma Service Group. The Steering Committee will
regularly review the status of the trial and available
blinded data, and will perform appropriate actions accord-
ing to the conduct of the study. A face-to-face Executive
Committee meeting will be required to make major deci-
sions. To ensure the study meets the highest standards of
ethics and patient safety, the Safety and Monitoring Board
will meet regularly and monitor the progress of the study.
The Board is composed of Academic Members, including
an independent statistician, who are not otherwise partici-
pating in the trial. Clinical end-point events (stroke, myo-
cardial infarction, death, and overt bleedings) will be
reviewed by independent experts (neurologists, cardiolo-
gists) in the Critical Events Committee. The sponsor of
the NICE trial is the Minister of Science and Technology
of the People's Republic of China. The sponsor has no in-
fluence on the study design, data collection, data analysis,
and final drafting of this manuscript.
Conclusion
The primary objective of this phase IV multicenter
double-blind, placebo-controlled, randomized clinical
trial is to prove the efficacy of nimodipine in the preven-
tion/treatment of mild cognitive impairment following
acute ischemic stroke. Approximate 23 centers in China
are enrolled in the NICE trial, and the first patient was
recruited into the study in November 2010. This trial
analyses the safety of nimodipine and investigates several
secondary outcomes. The results of the NICE study are
expected in 2013.
Additional file
Additional file 1: Appendix.
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